Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,075 public trials 581 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Completed

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

NCT00724568

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Emory University Hospital Atlanta, Georgia, United States
  • The University of Chicago Medical Center Chicago, Illinois, United States
  • Dana Farber Cancer Institute (and Massachusetts General) Boston, Massachusetts, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Completed

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

NCT00603447

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Pacific Shores Medical Group Long Beach, California, United States
  • Cedars Sinai Medical Center Los Angeles, California, United States
  • University of California San Francisco San Francisco, California, United States
  • H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
View Trial Details
Completed

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

NCT01980589

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • California Cancer Associates for Research and Excellence Encinitas, California, United States
  • James R. Berenson, MD West Hollywood, California, United States
  • The Oncology Institute of Hope and Innovation Whittier, California, United States
  • Horizon Oncology Research Lafayette, Indiana, United States
View Trial Details
Completed

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

NCT00811733

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Stanford, California, United States
  • GSK Investigational Site Rochester, Minnesota, United States
  • GSK Investigational Site Buffalo, New York, United States
View Trial Details
Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

NCT00118352

Conditions
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, +135 more
Locations
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
  • University of Torino Torino, Italy
View Trial Details

Related conditions